Hong Kong, Shanghai & Florham Park, New Jersey, USA, September 3, 2026
HUTCHMED (China) Limited and GSK have entered into an exclusive development and licensing agreement for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate (ATTC) being developed as a potential treatment for solid tumors. Under the agreement, GSK will receive worldwide rights to develop and commercialize HMPL-A830 outside Mainland China, Hong Kong, Macau and Taiwan, while HUTCHMED retains rights in those territories. The collaboration has a potential value of up to US$1.295 billion, comprising a US$110 million upfront payment, up to US$1.185 billion in development, regulatory and commercial milestones, and tiered royalties on annual net sales. The agreement represents a significant licensing milestone for HUTCHMED’s targeted oncology platform and expands GSK’s collaboration with innovative cancer drug technologies.
HUTCHMED Advances HMPL-A830 Toward Phase I
HMPL-A830 is currently a preclinical drug candidate designed around HUTCHMED’s antibody-targeted therapy conjugate technology. The candidate combines a highly selective and potent KRAS small-molecule inhibitor payload with an anti-EGFR antibody. According to the companies, this design is intended to direct the therapeutic payload toward EGFR-expressing tumor cells, while simultaneously interfering with EGFR and KRAS signaling. HUTCHMED will be responsible for the global Phase I clinical development program, which is expected to begin in the second half of 2026 under clinical trial identifier NCT07718581. GSK will assume responsibility for subsequent clinical development and commercialization outside HUTCHMED’s retained territories. The approach is being developed to address limitations associated with systemic administration of KRAS-targeting agents. KRAS alterations are common molecular drivers across several solid tumors, particularly colorectal cancer, lung cancer and pancreatic ductal adenocarcinoma. Although recent KRAS-targeted therapies have established the pathway as a viable therapeutic target, challenges remain, particularly among patients with non-G12C KRAS mutations and those whose tumors develop acquired resistance. HUTCHMED states that resistance can involve increased upstream receptor tyrosine kinase signaling and secondary KRAS alterations. HMPL-A830 is therefore designed to combine targeted delivery with dual pathway inhibition in an effort to improve therapeutic selectivity and durability.
Dual KRAS-EGFR Targeting Expands Oncology Strategy
The biological rationale for HMPL-A830 centers on the interaction between EGFR and KRAS signaling. EGFR is an established receptor tyrosine kinase involved in tumor-cell proliferation, survival and disease progression in several cancers, including colorectal, pancreatic and non-small cell lung cancers. Because EGFR signaling operates upstream of KRAS, increased EGFR activity can contribute to reactivation of downstream pathways and resistance to KRAS-directed treatment. HUTCHMED is developing HMPL-A830 to address this relationship by combining EGFR targeting with delivery of a KRAS inhibitor payload. Unlike conventional antibody-drug conjugates that typically use cytotoxic payloads, HUTCHMED describes its ATTC platform as combining monoclonal antibodies with proprietary small-molecule inhibitor payloads. The company says the technology is intended to enable tumor-selective activity while pursuing dual mechanisms of action. HMPL-A830 is the third drug candidate generated from these novel payload platforms and the first to be licensed to a global pharmaceutical partner. Two other candidates from the platforms have already entered clinical development, according to HUTCHMED.
Advertisement
GSK Gains Global Rights to HUTCHMED Oncology Asset
The agreement initially prioritizes clinical development of HMPL-A830 in colorectal, pancreatic and lung cancers, reflecting the high prevalence of KRAS-altered tumors in these malignancies. GSK’s subsidiary will lead development and commercialization activities outside the retained Asian territories following the initial Phase I program. HUTCHMED will continue to hold full development and commercialization rights in Mainland China, Hong Kong, Macau and Taiwan. The agreement also gives GSK a right of first negotiation for one earlier-stage ATTC candidate, potentially extending the strategic relationship beyond HMPL-A830. For HUTCHMED, the licensing agreement provides a pathway to leverage GSK’s global development and commercialization capabilities while retaining rights in key markets. For GSK, the collaboration adds an emerging precision oncology technology focused on the intersection of KRAS and EGFR biology. However, HMPL-A830 remains an investigational, preclinical candidate, and its safety, efficacy and ability to achieve regulatory approval will depend on results from future clinical development. The planned Phase I study will be an important next step in determining whether the dual-targeting strategy can translate its preclinical rationale into clinical benefit for patients with KRAS-driven solid tumors.
Source: HUTCHMED, GSK press release
